nesbuvir
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2006 (NCT00314054)
Timeline
Indications
Mechanism of action
- RNA-directed RNA polymeraseINHIBITOR
RNA-directed RNA polymerase inhibitor
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(CCO)S(C)(=O)=O)c(C3CC3)cc12- Mol. weight
- 446.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1092581 ↗
Also known as
- hcv796
- hcv 796
- hcv 796
- hcv 796
- hcv 796
- hcv-796
- hcv-796
- hcv-796
- nesbuvir
- nesbuvir
- nesbuvir
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00410254 | Phase 1 | Jun 1, 2007 | Pfizer, Wyeth |
| NCT00500721 | Phase 1 | Jun 1, 2007 | Pfizer, ViroPharma, Wyeth |
| NCT00407173 | Phase 1 | Nov 1, 2006 | Pfizer, ViroPharma, Wyeth |
| NCT00367887 | Phase 2 | Oct 1, 2006 | Pfizer, ViroPharma |
| NCT00385190 | Phase 1 | Jul 1, 2006 | Pfizer, Wyeth |
| NCT00314054 | Phase 1 | May 1, 2006 | Pfizer, ViroPharma, Wyeth |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 6 | 6 | 2 | 2006 |
| Wyeth | For profit | 5 | 0 | 1 | 2006 |
| ViroPharma | For profit | 4 | 0 | 2 | 2006 |
3 organizations
Page 1 / 1